<DOC>
	<DOCNO>NCT03042676</DOCNO>
	<brief_summary>Allogeneic hematopoietic stem cell transplantation ( HSCT ) capable definitive cure acute leukemia . The important post-transplant complication graft v host disease ( GVHD ) substantially decrease addition anti-T lymphocyte globulin ( ATG-Grafalon ) standard GVHD prophylaxis ( cyclosporin methotrexate ) without increase relapse infection ( Kroger et al NEJM 2016 , ClinicalTrials.gov number , NCT00678275 ) . In ATG_familystudy ( prospective , randomise , multicenter study ) decrease incidence chronic GVHD ( 67.8 % 32.2 % ) observe addition ATG ( 10 mg/kg three day , day -3 -1 ) standard GVHD prophylaxis set acute leukemias remission , receive peripheral blood stem cell HLA identical sibling donor myeloablative preparative regimen . In particular , GVHD extensive form reduce 52.4 % 7.6 % . The study close 2014 minimum follow 2 year transplant . The investigator would like evaluate long term follow study .</brief_summary>
	<brief_title>Electronic Database Follow ATG_FamilyStudy</brief_title>
	<detailed_description>In ATG_familystudy ( prospective , randomise , multicenter study ) decrease incidence chronic GVHD ( 67.8 % 32.2 % ) observe addition ATG ( 10 mg/kg three day day -3 -1 ) standard GVHD prophylaxis set acute leukemias remission , receive peripheral blood stem cell HLA identical sibling donor myeloablative preparative regimen . In particular , GVHD extensive form reduce 52.4 % 7.6 % . The study close 2014 minimum follow 2 year transplant . The primary endpoint creation multicenter electronic database data patient previously enrol ATG_family study , NCT00678275 ; data collection last ten year . Schedule follow-up death stop time patient retire consent . The database allow evaluate : - Long term mortality enrol patient , without GVHD - Long term relapse allogeneic HSCT acute leukemia patient - Prognostic factor overall population accord randomization arm - Recovery work activity Study design Multicenter , observational , prospective cohorting study ( electronic database ) retrospective phase . Prospective phase : electronic database include patient enrol ATG_familystudy routinely follow Hematological Institutions participate study . Retrospective phase : data collection review patient enrol ATG familystudy ( medical chart review ) already dead lose follow end ATG_familystudy medical chart review ( Feb 2014 ) . The electronic database include patient enrol ATG_familystudy . Inclusion criterion : - patient include ATG_familystudy ( NCT00678275 ) - informed consent give Exclusion criterion : none Treatment : treatment envisage ; patient follow accord standard clinical practice international guideline . Visit evaluation Prospective phase : patient follow visit ( mainly outpatient ) , laboratory instrumental test , phone contact provide clinic route . Retrospective phase : medical chart review Informed consent : patient ask sign write consent visit outpatient inpatient , require . Confidentiality collect information : principal investigator responsible data treatment . Collected data analyze statistical method anonymous way order obtain information represent aim study . The electronic database accessible authorized person . The principal investigator coworkers access data : everyone oblige data confidentiality . Electronic database - The electronic database include patient enrol ATG_familystudy . The data collection hospital admittance medical evaluation perform outpatient do medical records/charts analysis . In way , biographical data , anamnestic data information sign symptoms onset disease , diagnostic roadmap treatment collect . - For patient unreachable phone detail give patient patient already dead , data take analysis medical chart Office vital statistic , EC approval . Patients lose follow patient unreachable anyway detail give patient him/herself . - In electronic database data patient enrol ATGfamilystudy include date EC approval . For dead lose follow patient data record retrospectively . Statistical analysis The investigator use cumulative incidence analysis ass chronic GVHD-free survival relapse-free survival label death event interest compete risk . Death relapse use compete risk cumulative incidence analysis death without relapse . Overall survival assess use Kaplan- Meier analysis . Further treatment- group comparison perform use chi-square test nominal data , Mann-Whitney U-tests ordinal data , analysis variance interval ratio-scale data . Exploratory , post hoc , Cox multiple regression analysis use subgroup analyse purpose determine effect incidence chronic GVHD overall survival recipient age , first versus second remission , acute lymphoblastic versus acute myeloid leukemia , cytogenetic risk , risk underlie disease , difference sex donor sex recipient , cytomegalovirus positivity recipient , type conditioning , CD34+ cell transplant , grade acute GVHD chronic GVHD ( time dependent [ i.e. , correspond event occur different point time transplantation ] ) addition treatment assignment ( ATG vs. non-ATG ) original ATG_familystudy . Confidence interval difference risk accord treatment group determine use Wilson 's method . Cumulative incidence analysis perform use NCSS statistical software , version 9 , R statistical software , version 2.10.1 ( cmprsk package ) . IBM SPSS Statistics software , version 22.0 , use analysis .</detailed_description>
	<criteria>patient already enrol ATG_family_study ( NCT00678275 ) , publish Kroger N et al . Antilymphocyte Globulin Prevention Chronic GraftversusHost Disease . N Engl J Med 2016 ; 374:4353 informed consent give</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>anti-T lymphocytic globulin ( ATG )</keyword>
	<keyword>allogeneic stem cell transplant</keyword>
	<keyword>prophylaxis GVHD</keyword>
</DOC>